Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907662 | 0.88 | ITGB1 (0.45) | NOD1CYP2C9FOLH1NAALAD2RIMKLA | |
| SCHEMBL4956322 | 0.84 | NOD1 (0.51) | NOD1FOLH1NAALAD2RIMKLA | |
| SCHEMBL4953665 | 0.84 | NOD1 (0.40) | NOD1CYP2C9PIN1CA2CA4 | |
| SCHEMBL4952262 | 0.83 | FOLH1 (0.41) | NOD1FOLH1NAALAD2RIMKLALMNA | |
| SCHEMBL10656676 | 0.82 | CA2 (0.40) | NOD1CYP2C9FOLH1NAALAD2RIMKLA | |
| SCHEMBL10656672 | 0.82 | CA2 (0.40) | NOD1CYP2C9FOLH1NAALAD2RIMKLA | |
| SCHEMBL302958 | 0.82 | LMNA (0.53) | FOLH1CA2LMNAALDH1A1MAPK1 | |
| SCHEMBL302957 | 0.82 | LMNA (0.53) | FOLH1CA2LMNAALDH1A1MAPK1 | |
| SCHEMBL987347 | 0.82 | LMNA (0.53) | FOLH1CA2LMNAALDH1A1MAPK1 | |
| SCHEMBL19506668 | 0.82 | KDM4E (0.44) | NOD1FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188733-B1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2016036794-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-7465471-B2 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007147155-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20050215623-A1 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1531672-A2 | ANTIMICROBIAL COMPOSITIONS | Novus International, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040175434-A1 | Antimicrobial compositions | NOVUS INTERNATIONAL, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004019683-A2 | ANTIMICROBIAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-4139635-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1979-02-13 | — | — | US | disclosed |
| US-3950542-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | PNLIP, ELOVL1, ELOVL5 | NOD1 3692/4885CYP2C9 1149/4885FOLH1 1682/4885 |
| US-20050215623-A1 | Palatability of aquaculture feed | TAS2R3, TAS2R1, TAS2R20 | NOD1 3233/4885CYP2C9 3402/4885FOLH1 2075/4885 |
| US-20040175434-A1 | Antimicrobial compositions | MRPL21, FPR1, ARG1 | NOD1 10/4885CYP2C9 2829/4885FOLH1 4314/4885 |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | NOD1 4271/4885CYP2C9 3583/4885FOLH1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.